Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis

The American Journal of Drug and Alcohol Abuse
Vahid FarniaAbbas Aghaei

Abstract

Lifetime prevalence of amphetamine-induced psychotic disorder is reported as being up to 23% for methamphetamine (MA) abusers. Approximately 25% of those with a baseline DSM-IV diagnosis of substance-induced psychosis are diagnosed with primary psychosis at one-year follow-up. Evidence on the treatment of amphetamine psychosis is very limited. To investigate the efficacy of risperidone versus aripiprazole in treatment of amphetamine-induced psychotic symptoms. In a double-blind study, 45 participants were randomly allocated to either aripiprazole 15 mg or risperidone 4 mg daily over a six-week trial. Positive and negative symptoms of psychosis were assessed using the Scale for Assessment of Negative Symptoms (SANS) and the Scale for Assessment of Positive Symptoms (SAPS) at baseline and completion of the trial. SANS and SAPS scores decreased significantly in both groups. Mean SAPS score reduction in risperidone and aripiprazole group was 16.20 and 10.80, respectively, after trial course (p < 0.001). Mean SANS score reduction in risperidone and aripiprazole group was 9.35 and 11.25, respectively (p = 0.08). Both aripiprazole and risperidone were effective for patients diagnosed with amphetamine-induced psychotic disorder. Howeve...Continue Reading

References

Jul 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·W CoryellM Keller
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen
Oct 31, 2002·Psychiatric Services : a Journal of the American Psychiatric Association·Martin H LeamonLloyd Benjamin
Jun 18, 2003·Journal of Substance Abuse Treatment·Margaret CretzmeyerJames A Hall
Dec 12, 2003·Addictive Behaviors·Mary-Lynn BrechtM Douglas Anglin
Mar 17, 2004·Neuroscience and Biobehavioral Reviews·Una D McCann, George A Ricaurte
Nov 29, 2005·Addictive Behaviors·Ira SommersArielle Baskin-Sommers
Sep 14, 2006·Addiction·Rebecca McKetinLeanne Hides
Feb 3, 2007·The British Journal of Psychiatry : the Journal of Mental Science·Carol L M CatonBella Schanzer
May 9, 2008·The American Journal on Addictions·Rebecca McKetinLeanne Hides
May 12, 2009·Addiction·Christopher C Cruickshank, Kyle R Dyer
Jan 19, 2010·Drug and Alcohol Review·Suzette Glasner-EdwardsUNKNOWN Methamphetamine Treatment Project Corporate Authors
Feb 19, 2010·The American Journal on Addictions·Martin H LeamonGantt P Galloway

❮ Previous
Next ❯

Citations

Jul 1, 2015·Asian Journal of Psychiatry·Zahra Alam-mehrjerdiKate Dolan
Mar 1, 2015·Drug and Alcohol Dependence·John R RichardsB Zane Horowitz
Nov 9, 2016·Iranian Journal of Psychiatry and Behavioral Sciences·Mercede SamieiReza Daneshmand
Sep 1, 2019·International Journal of Psychiatry in Medicine·Paul A Zarkowski
Jun 23, 2019·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Mansour KhoramizadehSara Shishehgar
Nov 5, 2019·Frontiers in Psychiatry·Dimy FluyauKervens Lorthe
Sep 14, 2019·Comprehensive Psychiatry·Valentina CaricasoleBernardo Dell'Osso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here